- The strongest trial evidence is the Nambour study in Queensland, Australia. Its 2011 follow-up is titled "Reduced melanoma after regular sunscreen use" (Green et al., Journal of Clinical Oncology 2011). The abstract reports 11 melanomas in the daily-sunscreen arm and 22 in the discretionary arm, a hazard ratio of 0.50 (95% CI 0.24 to 1.02). For invasive melanoma it is 3 versus 11 cases, hazard ratio 0.27 (0.08 to 0.97).
- The trial registry lists the Australian government's National Health and Medical Research Council (NHMRC) as the only funder, with a researcher at QIMR Berghofer as primary sponsor (ANZCTR ACTRN12610000086066).
- The NHS advises an SPF of at least 30 and at least 4-star UVA protection, and says not to rely on sunscreen alone (NHS). The US FDA says broad-spectrum sunscreen is "only one element" of skin-cancer prevention (FDA).
- Vitamin D: a 2019 review found "little evidence" that sunscreen lowers vitamin D in real-life use (Neale et al., British Journal of Dermatology 2019). Newer work on very high-SPF daily use is not settled, and we could not verify it.
- Filters: the maximal-use trial found that all four tested products produced blood levels above the agency's 0.5 ng/mL threshold, and the authors said the clinical meaning is unknown (Matta et al., JAMA 2019). The FDA says its request for more data is not a conclusion that these ingredients are unsafe (FDA).
- Money trail: the maximal-use trial's lead author is reported to be an FDA scientist; PubMed lists no conflicts, and its funding statement could not be checked (PMC record). The regulator is also deciding the rules on these same filters. We opened no industry-funded study, so this article grades none.
- Evidence grade: Suggestive for regular use lowering melanoma risk, because the overall confidence interval includes 1. Weak for any vitamin D effect in real life. Risk (unresolved) for chemical filters, pending the FDA review.
Independent evidence review · Skin protection
Regular sunscreen use is supported by a long Australian trial whose follow-up reported less melanoma, and official UK and US advice treats sunscreen as one part of skin-cancer prevention. The evidence is less settled on vitamin D and on several chemical filters, which the FDA is still reviewing. Our confidence: low to moderate that regular use lowers melanoma risk, because the overall confidence interval includes 1; low on the size of that effect; low on filter safety, because the regulator has not finished its review and the data so far show absorption, not harm.
Table of contents
- Evidence summary
- What sunscreen is, and what the labels mean
- How it works
- What works and what does not
- Benefits by claim
- Risks and open safety questions
- Interactions and combined protection
- Who needs extra advice
- How much is used, and how often
- Follow the money: who makes it and who funded the evidence
- Related research
- Frequently asked questions
- Sources and funding notes
Evidence summary
| Claim | Evidence | Source | Funding / conflict | Strength |
|---|---|---|---|---|
| Regular daily sunscreen use reduces melanoma | Long-term follow-up of a community randomised trial in Nambour, Queensland. The published title reports "reduced melanoma after regular sunscreen use". The abstract reports a hazard ratio of 0.50 (95% CI 0.24 to 1.02), with the interval including 1. | Green et al., JCO 2011 | NHMRC is the only funder listed in the trial registry. The journal's funding statement was not visible to us. | Suggestive |
| Sunscreen is one part of skin-cancer prevention, not the whole of it | The NHS says not to rely on sunscreen alone and to wear suitable clothing and seek shade. The FDA calls broad-spectrum SPF 15+ "only one element" of prevention. | NHS; FDA | Public health bodies with no product sales. Guidance, not a trial. | Strong (guidance) |
| Daily sunscreen lowers vitamin D in real life | A 2019 review of three field trials (two randomised) found "little evidence" of a drop in 25(OH)D with real-life use. It also said trials of the very high-SPF products now widely recommended are lacking. | Neale et al., BJD 2019 | Funding statement not seen. A QIMR Berghofer lab page lists NHMRC, Viatris, Pankind and Helen Lyons Foundation as funders of that lab; we could not confirm whether they cover this review. | Weak (for a vitamin D effect) |
| Some chemical filters enter the blood after maximal use | Four products (two sprays, a lotion and a cream), 4 applications on day 1: all four exceeded the FDA's 0.5 ng/mL threshold. Oxybenzone reached a geometric mean of about 169 to 210 ng/mL (spray and lotion). The authors say the clinical significance is unknown. | Matta et al., JAMA 2019 | Funding statement not verified; PubMed lists no conflicts. Lead author reported as FDA-affiliated. The regulator also has a pending review of these filters. | Risk (absorption, not harm) |
| Oxybenzone, avobenzone and ten other filters are "not yet GRASE" | The FDA proposed these filters were not GRASE (generally recognised as safe and effective), pending more data. The FDA says this is not a conclusion that they are unsafe. | FDA | Regulator with its own rule pending. | Unresolved |
Independent evidence and credibility scorecard
Tier 1 = independent of the outcome. Tier 2 = indirect ties, such as a government body with a regulatory stake. Tier 3 = interested party, such as a trade body or advocacy group. Tier 4 = self-interested, such as a manufacturer or seller. Credibility A = high, B = solid but watch the bias, C = interested, D = self-interested.
| Source | Who funds it | Country | Independence tier | Credibility | Why it would tell the truth, and residual bias |
|---|---|---|---|---|---|
| Green et al., JCO 2011 | NHMRC per the trial registry. Primary sponsor is a researcher at QIMR Berghofer. Journal funding statement not seen. | Australia | Tier 1 | B | Peer-reviewed and published in a major oncology journal. Academic careers reward positive findings. The trial was run in one subtropical community. |
| ANZCTR ACTRN12610000086066 | Sponsor's own declaration: NHMRC is the only funder listed. Registered in 2010, after the trial began in 1992. | Australia | Tier 1 | B | Registration is a legal and journal requirement. The record is self-declared by the sponsor and was filed retrospectively, so it shows the declared funding, not a check of it. |
| Matta et al., JAMA 2019 | Funding not verified. Lead author reported as FDA-affiliated. PubMed lists no conflicts. | United States | Tier 2 | B | Peer-reviewed and registered (NCT03582215). The lead author is reported to work at the agency deciding the rules on these filters, a regulatory stake. The authors say clinical significance is unknown. |
| FDA sunscreen Q&A (10 Sep 2026) | US federal budget. Not a trial, and not a sales interest. | United States | Tier 2 | B | Legal mandate and public accountability reward caution. But the FDA is both the reviewer and the party with a pending rule. |
| Neale et al., BJD 2019 | Not shown on the page we opened. Tier 2 is provisional until the funding statement is checked. | UK journal; review hosted on an Australian university portal | Tier 2 | B | Systematic review of a small experimental base: three field trials, two of them randomised. Incentives favour a clear, citable conclusion. The review says the high-SPF trials that matter now are missing. |
| NHS sunscreen and sun safety guidance | UK public health service, funded through public taxation. No product sales. | United Kingdom | Tier 1 | B | Public health duty and national accountability reward accurate, cautious advice. Residual bias: a short consumer summary, not a trial review, and it does not show its evidence base. |
Convergence and clustering. The NHS and the FDA agree that sunscreen is one part of protection, but both are government bodies with no sales interest, so their agreement is weak evidence on effect size. We found no source with an opposing financial interest that we could open. Four of six sources come from two high-income English-speaking countries (two US, and the UK-published review and the NHS), and two from Australia. The verdict therefore reflects those countries' regulatory lenses.
What sunscreen is, and what the labels mean
Sunscreens are products that filter ultraviolet (UV) light. The FDA's 2021 proposed order lists oxybenzone and avobenzone among twelve filters it wants more safety data on (FDA). Two labels matter most. SPF (sun protection factor) measures protection against UVB, the wavelength most linked to sunburn. The NHS asks for an SPF of at least 30 (NHS sun-safety guidance). UVA protection is shown as a star rating, and the NHS asks for at least 4 stars, (NHS).
Labels in the US and the rules being written
The FDA's proposed rule would make broad-spectrum protection mandatory for all products with SPF 15 or higher. It would require a UVA ratio of at least 0.7, and it proposes a maximum labelled value of SPF 60+ (formulations up to SPF 80 would still be allowed). The FDA page we opened does not cover water-resistance claims (FDA).
Where the regulation stands in 2026
The FDA's page, current to 10 September 2026, records three steps. In June 2026 it added bemotrizinol as a sunscreen active ingredient. In September 2026 it finalised the removal of PABA and trolamine salicylate, which it says are not GRASE. FDA says it is not aware of any US product containing them. Twelve filters, including oxybenzone, avobenzone, octinoxate, homosalate and octocrylene, still need more safety data. The FDA says any final order cannot take effect for at least a year (FDA).
How it works
Sunscreen is applied to the skin to filter UV light. The Nambour follow-up tested a population outcome: whether regular use in a community was followed by less melanoma (Green et al., JCO 2011). We did not open mechanistic studies, so this section does not explain how any single filter works inside skin.
What is proven in humans is the community trial result, not a biological mechanism. Lab work on individual filters is not covered here.
What works and what does not
| Use | What the evidence shows | Status |
|---|---|---|
| Regular daily use of sunscreen in the community | Follow-up of a randomised trial reports less melanoma with regular use. Overall hazard ratio 0.50 (95% CI 0.24 to 1.02). | Suggestive, one trial |
| Sunscreen alone, without shade or clothing | NHS says not to rely on sunscreen alone. | Not enough alone |
| Thin application, or applying once and not reapplying | NHS advises reapplication every 2 hours. | Reduces protection |
| Daily high-SPF use and vitamin D status | The 2019 review found little effect in real life, but it says newer high-SPF trials are lacking. | Not settled |
| Chemical filters for systemic safety | Absorption is measured, but clinical significance is unknown and the FDA review is open. | Not settled |
Benefits by claim
Does sunscreen prevent melanoma?
The 2011 follow-up of the Nambour trial is titled "Reduced melanoma after regular sunscreen use" (Green et al., JCO 2011). It is one randomised trial in one Australian community, with long follow-up. The abstract reports 11 melanomas in the daily arm and 22 in the discretionary arm, with a hazard ratio of 0.50 (95% CI 0.24 to 1.02; P = .051). A single trial in one setting, with an interval that includes 1, is a reason for low-to-moderate confidence.
Does sunscreen stop skin cancer in general?
Neither the NHS nor the FDA claims that sunscreen prevents all skin cancer. The FDA calls it "only one element" of a prevention strategy, alongside clothing, sunglasses, a hat and shade during peak sunlight (FDA).
Does sunscreen cause vitamin D deficiency?
The 2019 review by Neale and colleagues found "little evidence" that sunscreen lowers vitamin D in real-life settings. The review also notes that very high-SPF products have not been adequately studied (Neale et al., BJD 2019). The NHS advises that all children under 5 take vitamin D supplements (NHS).
Is oxybenzone banned?
No. The FDA has not banned oxybenzone. It is one of the filters the agency proposed were not GRASE pending more data, and the FDA says this is not a conclusion that it is unsafe (FDA). Its status is unresolved in the FDA's 2026 orders.
Marketing claims, graded against the rules
| Claim on a label | What the rule or regulator says | Grade |
|---|---|---|
| "Broad spectrum" | The proposed rule would require it for SPF 15+ (FDA). | Pending rule |
| SPF 30 or higher, with 4-star UVA | NHS guidance for UK sunscreens. | Matches guidance |
| SPF above 60 | The FDA proposes a maximum labelled value of SPF 60+. The page does not say how higher labels would be treated. | Above proposed cap |
| "Reef safe" or "natural" | We did not find a regulatory definition in the sources we opened. | Could not verify |
Risks and open safety questions
The immediate harm is sunburn. Thin application and missed reapplication cut the protection a product gives, and the NHS asks for generous use and reapplication (NHS).
Interactions and combined protection
The main "interaction" is with other sun protection. The NHS says not to rely on sunscreen alone (NHS), and the FDA calls it only one element of skin-cancer prevention (FDA).
Who needs extra advice
Ask a clinician or pharmacist about sunscreen for infants or during pregnancy; we did not verify regulator guidance on this. The NHS advises that all children under 5 take vitamin D supplements (NHS). A GP or pharmacist can advise on individual circumstances.
How much is used, and how often
The NHS gives a practical measure for a whole body: about 6 to 8 teaspoons for an adult. It also says to reapply every 2 hours. The NHS also advises checking the UV index and considering protection when it is 3 or higher (NHS).
Follow the money: who makes it and who funded the evidence
Who makes and sells it
We did not trace the manufacturers, parent companies or ownership of the main sunscreen brands, so we cannot give a verified money map for the products themselves. The regulatory history is documented. The FDA's September 2026 order removed two filters the agency found not GRASE, and it says it is not aware of any US product containing them (FDA).
Who funded the trials and reviews
The Nambour trial's registry names the NHMRC as its only funder (ANZCTR). The JAMA maximal-use trial's funding statement could not be checked. PubMed lists no conflicts, and its lead author is reported as an FDA scientist (Matta et al.). The funding of the 2019 vitamin D review is not shown on the page we opened (Neale et al.). We opened no industry-funded trial, so this article does not grade one.
Documented integrity events
The documented regulatory events are the FDA's 2026 orders on PABA and trolamine salicylate and on bemotrizinol, and the FDA's request for more data on twelve filters, which the agency says is not a finding of unsafety (FDA). We found no recall or enforcement action that we could verify.
Research funding at a glance
6 sources graded. The counts below are the independence tiers assigned in the scorecard above. They count sources, not funding amounts or evidence quality.
Public funding alone does not prove independence, and commercial funding alone does not prove a claim false. Named funders, countries and relationships are in the scorecard and source notes.
Related research
- Melanoma: skin and nail symptoms, biopsy, staging and treatment
- Basal cell carcinoma: skin signs, biopsy, Mohs and treatment
- Cutaneous squamous cell carcinoma: biopsy, risk and treatment
- Merkel cell carcinoma: symptoms, diagnosis and care
- Astaxanthin: skin, UV response, exercise and safety evidence
- Cancer prevention and supportive care: evidence and safety guide
- Cancer supplements and food claims: evidence and safety
Frequently asked questions
Does sunscreen prevent melanoma?
A long randomised trial in Australia reported "reduced melanoma after regular sunscreen use" (Green et al., JCO 2011). It is one trial, with an overall hazard ratio of 0.50 whose interval includes 1.
What SPF should a sunscreen have?
The NHS advises an SPF of at least 30 and at least 4-star UVA protection (NHS).
Does sunscreen stop vitamin D?
A 2019 review found "little evidence" that sunscreen lowers vitamin D in real-life use (Neale et al., BJD 2019).
Is oxybenzone banned in the US?
No. The FDA has not banned it. It is among the filters the agency says need more data, and the FDA says this is not a conclusion that it is unsafe (FDA).
What does "broad spectrum" mean on a label?
The FDA has proposed making broad-spectrum protection mandatory for SPF 15 and above (FDA).
Is sunscreen enough on its own?
No. The NHS says not to rely on sunscreen alone (NHS).
Should sunscreen be used on babies?
Ask a clinician or pharmacist; we did not verify regulator guidance on infant use.
Sources and funding notes
What we could not verify. The journal's funding statement for the 2011 Nambour follow-up, and the funding statement for the 2019 maximal-use trial and the 2019 vitamin D review. The full FDA Federal Register notice of the 2019 proposal. The newer SPF 50+ vitamin D trial reported in press coverage. The NICE and Cancer Research UK sun-protection guidance. Industry-funded sunscreen trials and trade-body positions. Consumer testing of SPF accuracy. Manufacturer ownership of the main brands. We also did not confirm the category assignment used in the metadata.
- Green AC, Williams GM, Logan V, Strutton GM. Reduced melanoma after regular sunscreen use: randomized trial follow-up. J Clin Oncol 2011;29(3):257-263. Role: randomised follow-up of the Nambour trial. Funder: NHMRC per the registry; journal funding statement not seen.
- ANZCTR ACTRN12610000086066, Nambour Community-based Skin Cancer Prevention Trial. Role: trial registration. Funder: NHMRC, the only funder listed. Sponsor: Prof Adele Green, QIMR Berghofer.
- Matta MK et al. Effect of sunscreen application under maximal use conditions on plasma concentration of sunscreen active ingredients: a randomized clinical trial. JAMA 2019;321(21):2082-2091. Role: maximal-use trial. Funder: not verified (no grant listed in PubMed). Lead author reported as FDA-affiliated. No conflicts reported.
- US FDA. Questions and answers: FDA's regulatory actions on over-the-counter sunscreen (page current to 10 September 2026). Role: regulator's status report. Funder: US federal budget. Regulator with a pending rule.
- Neale RE, Khan SR, Lucas RM, Waterhouse M, Whiteman DC, Olsen CM. The effect of sunscreen on vitamin D: a review. Br J Dermatol 2019;181(5):907-915. Role: systematic review. Funder: not shown on the page we opened.
- NHS. Sunscreen and sun safety. Role: public health guidance. Funder: UK public health service.
Educational research reviewed 9 October 2026. This article is not medical advice; talk to a qualified clinician or pharmacist before starting, stopping or combining treatments.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.